Canadian authorities have approved Lynparza (olaparib) as an oral treatment for people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in BRCA or ATM genes, both of which are involved in DNA repair. The approval, granted under priority review, is specifically indicated for patients who progressed after treatment with new forms of hormone therapy, such as Xtandi (enzalutamide)…
Anixa Biosciences has entered in a license agreement with the Cleveland Clinic to obtain the exclusive, global rights for a new ovarian cancer vaccine technology. “Through this collaboration we are expanding into additional preventive and therapeutic areas and we look forward to seeing the development of this ovarian cancer vaccine,” Vincent Tuohy, PhD, an immunologist at…
Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company announced in a press release. Specifically, the new drug applications will cover myeloma patients who have received at least four therapies, and failed to respond to at least two immunomodulatory therapies, two…
Scientists have discovered that an unassuming non-medicinal plant can stop the growth of human breast cancer cells without affecting non-cancerous cells. Their research into Arabidopsis thaliana, a small annual flowering plant in the mustard family, could lead to potential new treatments for breast cancer and other diseases. The study, “Jasmonates induce Arabidopsis bioactivities selectively inhibiting the…
The U.S. Food and Drug Administration (FDA) has granted fast track status to RV001, RhoVac‘s investigational therapy for prostate cancer, the company announced. Fast track designation helps speed the approval of potential medicines that address unmet medical needs in serious or life-threatening conditions. It grants RhoVac greater access to FDA input throughout the regulatory process…
When given as a second- or third-line therapy, BeiGene’s tislelizumab is superior to docetaxel at prolonging the survival of people with locally advanced or metastatic non-small cell lung cancer (NSCLC), whose disease progressed while receiving platinum-based chemotherapy. Additionally, tislelizumab had a favorable safety profile that was consistent with that of previous studies, and its use…
Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, for the treatment of people with recurrent low-grade serous ovarian cancer (LGSOC), the company announced. The trial seeks to recruit up to 100 female patients — more information is available here — and will investigate the company’s RAF/MEK inhibitor VS-6766,…
Onconova Therapeutics is seeking the green light from the U.S. Food and Drug Administration (FDA) to begin a Phase 1 clinical trial for its small molecule ON 123300 in certain types of breast cancer. The trial would include, but not be limited to, people with relapsed/refractory advanced breast cancer, including those with hormone receptor-positive (HR+), human…
The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among individuals with or at risk of developing multiple myeloma. The aim of the Immune Profiling with Antibody-based COVID-19 Testing study, or IMPACT, is to understand what happens to the immune system during a…
The U.S. Food and Drug Administration (FDA) has approved a new dosing regimen for Imfinzi (durvalumab) for the treatment of certain non-small cell lung cancer (NSCLC) and bladder cancer patients. Granted under priority review, the approval allows Imfinzi to be administered at a fixed dose of 1,500 mg every four weeks for patients weighing more than 30 kg (about…
